New Cancer Therapies: Implications for the Perioperative Period
Tayab Andrabi, K. French, M. Qazilbash
Dec 1, 2018
Citations
2
Citations
Quality indicators
Journal
Current Anesthesiology Reports
Full text
Semantic Scholar
Key Takeaway Key Takeaway: New cancer therapies require a high index of suspicion and collaboration among anesthesiologists, oncologists, and other specialists for effective perioperative care.
Abstract
Purpose of ReviewCancer is on the rise. Standing on verge of exciting discoveries, research is being translated into therapies that are being widely administered to patients. Providing a hope for cure, where none existed before. This new body of knowledge has come from a better understanding of cancer genetics, molecular and sub molecular behavior, and understanding of cancer-generated cellular environments. These have led to development of immunotherapy and its many sub-genres, improvement and introduction of new radiation technologies, and decreasing toxicities of existing chemotherapies.Recent FindingsThe purpose of this review is to have a summary look at this huge landscape of cancer therapy. Specially looking at toxicities that an anesthesiologist should be familiar with while providing perioperative care for these patients, complications like tumor lysis syndrome, cytokine release syndromes, Kounis syndrome, myocarditis, encephalopathies, and pituitary failure need to be kept in mind.SummaryOne should be knowledgeable about these therapies and approach these patients with a high index of suspicion. Anesthesiologists will need to refine preoperative assessment with appropriate testing and intraoperative and postoperative management in collaboration with oncologists, while involving the expertise of internists, cardiologist, and endocrinologists in helping assess and manage these patients in the perioperative period.